Pfizer to NSCLC patients: Get tested

Share this article:

Pfizer Oncology has recruited Desperate Housewives and West Wing star Kathryn Joosten for Lung Cancer Profiles, a national education campaign which aims to reduce stigma and plug molecular testing of the disease. The push comes as Pfizer deepens its investment in narrowly targeted cancer treatments, whose success will require broad adoption of genetic testing.

Two-time Emmy winner Joosten's ten-year battle with lung cancer is featured on lungcancerprofiles.com, as are stories from other lung-cancer survivors, all older women. Joosten, 71, was first diagnosed with NSCLC in 2001. She quit smoking after 45 years, had a stage I tumor removed and was cancer-free until 2009, when a stage III tumor was found.

A test revealed that her cancer was EGFR-negative and KRAS-positive, which, she says, “helped my doctors find the right trial for my type of lung cancer.” Joosten takes an investigational drug as part of the trial, and says her “most recent scan shows some nodules have shrunk, some are stable, and nothing has grown.”

"Getting my tumor tested required perseverance,” she says on the site, “and I am proud to say that I took an active role in my own health.”

Pfizer's Xalkori (crizotinib) won FDA approval in August for treatment of some patients with late-non-small cell lung cancer (NSCLC) with a genetic mutation that can fuel the growth of cancerous cells. The agency simultaneously approved a test from Abbott Molecular Diagnostics for the mutated gene. Pfizer and Qiagen are also working on a drug-companion diagnostic combo for Pfizer's dacomitinib investigational drug for NSCLC. The culprit for those products is KRAS gene mutations.

Pfizer is working with lung cancer patient advocacy orgs on the effort, including the Bonnie J. Addario Lung Cancer Foundation, Lung Cancer Alliance, Lung Cancer Foundation of America, LUNGevity and the National Lung Cancer Partnership.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: Ipsen head leads continental charge

Headliner: Ipsen head leads continental charge

"When I look at the business, I actually see patients in my mind. I don't see numbers."

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets